the patients , who came from regions with high resistance to antimalarials , were divided into three groups receiving single-dose treatment as follows : a combination of 280 mg mefloquine , 800 mg sulfadoxine and 40 mg pyrimethamine ;
C0003374
antimalarials
C0025153
mefloquine